New hope for hard-to-treat breast cancer: drug targets HER2-low tumors

NCT ID NCT05831878

Recruiting now Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a drug called Disitamab vedotin (RC48-ADC) in 36 people with HER2-low advanced breast cancer that cannot be cured. Participants have had only one prior chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is. This is an early study, so results are not yet known.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Disitamab vedotin (RC48-ADC)
What this could lead to: If it works, this could offer a new treatment option for people with HER2-low advanced breast cancer who have few alternatives.
What could go wrong: This is a small, early-phase trial with only 36 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Locations

Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITING

Shanghai, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.